On Tuesday, Sana Biotechnology Inc (SANA) stock saw a decline, ending the day at $2.92 which represents a decrease of $-0.24 or -7.59% from the prior close of $3.16. The stock opened at $3.17 and ...

Sana Biotechnology (SANA), a clinical-stage biotech company specializing in gene and cell therapies, has recently experienced ...

We recently compiled a list of the 10 Hottest Smid-Cap Stocks So Far In 2025. In this article, we are going to take a look at ...

As researchers push for a type 1 diabetes cure, Sana Biotechnology has provided a nudge forward with new, if limited, ...

Sana Biotechnology Inc.'s stock soared over 200% on Wednesday, on track to mark its best day on record, amid trading volumes spiking to 54 times the daily average. The surge followed highly positive ...

Sana Biotechnology Inc (SANA) stock saw a decline, ending the day at $3.16 which represents a decrease of $-0.09 or -2.77% from the prior close of $3.25. The stock opened at $3.15 and touched a low of ...

Sana Biotechnology's first-in-human study shows UP421 pancreatic islet cells surviving and functioning in type 1 diabetes ...

Sana is a gene and cell therapy clinical-stage biotech firm and a penny stock that has fallen by 48.5% in the year leading to January 17, 2025. What may set this company apart from a host of similar ...

Morgan Stanley raised the firm’s price target on Sana Biotechnology (SANA) to $12 from $9 and keeps an Overweight rating on the shares. Based ...

Sana Biotechnology (NASDAQ:SANA) climbed over 200% on Wednesday following a sharp rally in the post-market yesterday in reaction to a Phase 1 readout for its UP421 cell therapy, which, according ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated look at SANA stock following its news.